Intangible Assets

INMB appears to have limited evidence of proprietary IP or clinically differentiated assets that would sustain pricing power versus larger biotech peers with broader pipelines and more validated platforms.

As a development-stage company, any patent protection is likely narrow and time-bound, so durability depends on future clinical success rather than an entrenched intangible moat.

Compared with peers that have approved products, deeper data packages, or platform breadth, INMB’s intangible assets look less proven and less monetizable over a 5–10 year horizon.

The absence of strong profitability and margin evidence in the provided metrics is consistent with intangible assets that are not yet translating into durable commercial advantage.

Switching Costs

INMB does not appear to have meaningful customer switching costs because its products are not yet established as standard-of-care therapies with embedded clinical workflows.

In biotech, switching costs usually arise after broad adoption, reimbursement integration, and physician familiarity, none of which are evidenced here versus commercial-stage peers.

Compared with approved-drug peers, INMB likely faces low retention power because prescribers and payers can shift to alternative therapies if efficacy, safety, or access is better elsewhere.

The negative TTM ROIC and ROCE suggest the company is not yet capturing economic value from any sticky customer relationships.

Network Effects

INMB does not show a meaningful network effect because drug adoption is driven by clinical evidence and reimbursement rather than user-to-user or platform-driven compounding.

Unlike data-rich diagnostics, software, or marketplace peers, additional INMB usage does not obviously increase the product’s value for other customers in a self-reinforcing loop.

Any physician familiarity or publication momentum would be indirect and weaker than true network effects seen in platform-based healthcare peers.

Relative to peers with registries, real-world evidence ecosystems, or multi-product platforms, INMB’s network effects appear negligible.

Cost Advantage

INMB shows no clear cost advantage because the provided metrics do not indicate scale efficiencies, positive unit economics, or superior capital productivity versus peers.

Development-stage biotech typically has high fixed R&D costs and limited manufacturing leverage, which makes sustained cost leadership difficult without commercial scale.

The negative ROIC and ROCE imply capital is not yet being deployed more efficiently than in better-positioned peers with approved products and established operations.

Compared with larger biopharma peers, INMB likely lacks procurement, manufacturing, and SG&A leverage that would translate into durable margin advantage.

Efficient Scale

INMB does not appear to benefit from efficient scale because the market for its potential therapies is not shown to be a natural monopoly or capacity-constrained niche with limited room for multiple competitors.

In biotech, efficient scale is strongest when a company controls a narrow, highly specialized market with high regulatory or manufacturing barriers, and that is not evidenced here.

Compared with peers that dominate orphan or highly specialized indications, INMB does not yet demonstrate a protected scale position that would deter entry or sustain pricing power.

The absence of positive operating returns suggests any scale benefits are not yet large enough to offset competitive pressure or development risk.

Overall Score

INMB’s moat looks weak versus peers because the available evidence does not show durable switching costs, network effects, cost advantage, or efficient scale, and any intangible asset base appears early-stage and unproven. The company’s negative TTM ROIC and ROCE reinforce that current economics are not yet translating into a defensible competitive advantage over a 5–10 year horizon.